Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPARE IT Trial: Nadofaragene Firadenovec vs Usual Care in NMIBC
NCT06929286Phase 3Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 3 trial of nadofaragene firadenovec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Memorial Sloan Kettering Cancer Center. Started Apr 2025; status: recruiting.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06929286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929286.